1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc.

IPCIF
Intellipharmaceutics International Inc.US flagOther OTC
0.15
USD
- -
- -
4.96MMarket Cap
Intellipharmaceutics International Inc.
IPCIF
(Other OTC)

Recent

price

0.15

P/E

ratio

- -

div

yld

- -

ROIC.AI

2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
FRC
- -
- -
- -
1.34
0.33
0.06
0.78
3.8
1.72
0.84
1.77
0.36
0.16
0.06
- -
- -
0.03
Revenue per Share
-14.59
-5.78
- -
-5.28
-3.25
-3.56
-5.84
-1.67
-3.13
-3.8
-2.86
-2.89
-0.37
-0.14
-0.17
-0.09
-0.1
Basic EPS, GAAP
-13.11
-5.46
- -
-5.8
-4.83
-5.04
-3.58
-1.08
-1.77
-2.54
-2.56
-2.65
-0.31
- -
-0.08
-0.04
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-193.53
-143.04
- -
-17.48
-15.97
-17.43
-21.14
-19.71
-22.25
-23.6
-11.8
-8.67
-2.23
-2.16
-1.8
-1.69
-1.76
Book Value per Share
11.84
2.91
- -
0.09
-2.06
-1.02
-3.03
2.13
-0.06
0.42
0.12
0.86
-0.17
-0.27
-0.28
-0.32
-0.39
Tangible Book Value per Share
2
2
- -
1
1
2
2
2
2
3
3
5
22
24
29
33
33
Basic Weighted Avg Shares
- -
- -
- -
1
1
- -
2
9
4
2
6
2
3
1
- -
- -
1
Sales/Revenue/Turnover
- -
- -
- -
-412.22
-1,549.72
-9,347.14
-446.4
-40.28
-173.76
-438.41
-150.17
-778.07
-225.11
-333.8
- -
-4,336.82
-279.57
Operating Margin (%)
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
- -
- -
- -
- -
Depreciation Expense
-29
-13
- -
-6
-5
-6
-11
-4
-7
-10
-9
-14
-8
-3
-5
-3
-3
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
-394.76
-972.53
-5,730.51
-752.55
-43.97
-181.65
-451.43
-160.91
-802.66
-232.28
-241.95
- -
-4,400.55
-350.72
Profit Margin (%)
23
7
5
-1
3
-1
-2
3
-2
2
-1
3
-6
-8
-9
-12
-14
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
23
7
5
- -
-3
-2
-6
5
- -
1
- -
4
-4
-6
-8
-11
-13
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Feb'23
May'23
Aug'23
ST Debt
2
2
2
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
33
33
33
Market Capitalization
2
2
3

Working Capital

FRC

•

in mil. unless spec.
Feb'23
May'23
Aug'23
Total Current Assets
1
1
1
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
13
13
14
Payables & Accruals
10
10
11
ST Debt
2
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-12.29%
180.32%
29.69%
Free Cash Flow
-244.35%
-501.47%
-43.6%
Net Income, GAAP
10.13%
-7.22%
-43.78%
Sales/Revenue/Turnover
- -
- -
-95.31%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-0.04
-0.04
-0.04
- -
-0.17
2022
-0.03
-0.03
-0.01
- -
-0.09
2023
-0.01
- -
-0.06
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
Doseology Sciences Inc. (MOOD.CN)
Boston Therapeutics, Inc. (BTHE)
Kintara Therapeutics, Inc. (KTRA)
Inventiva S.A. (IVA.PA)
Sana Biotechnology, Inc. (SANA)
DNAPrint Genomics, Inc. (DNAG)
Business
Intellipharmaceutics International Inc. (IPCIF) researches, develops, and commercializes novel and generic controlled-release and targeted-release oral solid dosage drugs utilizing its proprietary Hypermatrix technology platform. The company offers products including Focalin XR (dexmethylphenidate hydrochloride extended-release capsules for attention hyperactivity disorder); Keppra XR (levetiracetam extended-release tablets for partial onset seizures in epilepsy patients); Effexor XR (venlafaxine hydrochloride extended-release capsules for depression); Protonix (pantoprazole sodium delayed-release tablets for gastroesophageal reflux disease); Glucophage XR (metformin hydrochloride extended-release tablets for type 2 diabetes); Seroquel XR (quetiapine fumarate extended-release tablets for schizophrenia, bipolar disorder, and major depressive disorders); Lamictal XR (lamotrigine extended-release tablets for epilepsy); Pristiq (desvenlafaxine extended-release tablets for depression); Coreg CR (carvedilol phosphate extended-release capsules for heart failure and hypertension); and Ranexa (ranolazine extended-release tablets for chronic angina), as well as pipeline candidates such as abuse-deterrent oxycodone hydrochloride extended-release tablets (Oxycodone ER) under NDA review with the FDA and Regabatin XR (pregabalin extended-release capsules) for neuropathic pain. Its development pipeline includes ANDA and NDA 505(b)(2) filings targeting neurology, cardiovascular, gastrointestinal, diabetes, and pain management therapeutic areas through abuse-deterrent, long-acting oral drug delivery systems (L-ODDS) and nPODDDS platforms. Founded in 1998 and headquartered at 30 Worcester Road, Toronto, Ontario, Canada, the company generates revenue primarily through licensing agreements with Canadian and U.S. pharmaceutical partners and operates in North American markets. In March 2024, Intellipharmaceutics transferred its listing from the TSX Venture Exchange to NEX, a separate board, and adopted a new rolling stock option plan (reserving 10% of shares) subject to shareholder approval, replacing prior compensation plans amid ongoing efforts to file delayed financial reports following a cease trade order.

Company News

APIChat

  • defenseworld.net

    Analyzing Nuvo Pharmaceuticals (OTCMKTS:MRVFF) and Intellipharmaceutics International (OTCMKTS:IPCIF)

  • defenseworld.net

    Reviewing Intellipharmaceutics International (OTCMKTS:IPCIF) & Neoleukin Therapeutics (NASDAQ:NLTX)

  • accesswire.com

    Intellipharmaceutics Announces Downgrade to OTC Expert Market

  • accesswire.com

    Intellipharmaceutics International Inc. Announces Transfer of Listing to NEX and New Stock Option Plan

  • accesswire.com

    Intellipharmaceutics Announces Cease Trade Order

  • accesswire.com

    Intellipharmaceutics Announces Its Expected Delay in Filing Annual Audited Financial Statements and Annual Information Form

  • accesswire.com

    Intellipharmaceutics International Inc. Announces Stock Option Grant

  • accesswire.com

    Intellipharmaceutics International Inc. Receives Conditional Approval to List on the TSX Venture Exchange

  • accesswire.com

    Intellipharmaceutics Announces Third Quarter 2023 Results

  • accesswire.com

    Intellipharmaceutics Reports Director Election Results

  • accesswire.com

    Intellipharmaceutics Announces Closing of CAD$3.85 Million Non-Brokered Private Placement

  • accesswire.com

    Intellipharmaceutics Announces First Quarter 2021 Results